Nektar shares dip after latest PIVOT-02 results

Nektar Therapeutics Inc. (NASDAQ:NKTR) slipped $6.57 to $79.23 on Thursday after reporting updated response rates from the Phase Ib/II PIVOT-02 study of NKTR-214 plus Opdivo

Read the full 251 word article

User Sign In